Provention Bio, Inc.

Third-quarter 2022 net loss was $28.6 million, or $0.34 per basic and diluted share, versus a net loss of $27.0 million, or $0.43 per share, in the third quarter of 2021. R&D expense was $16.3 million versus $17.7 million a year ago, and G&A expense was $13.5 million versus $10.0 million a year ago. Collaboration revenue was $0.8 million. Cash, cash equivalents, and marketable securities were $186.5 million at September 30, 2022, including proceeds from the July private placement, Hercules term loan tranche, and ATM activity. The company said Q4 2022 cash-based operating expenses should be $40 million to $45 million. Management said cash plus contingent Sanofi and Hercules capital supports a potential teplizumab launch if approved and provides runway through 2023; if approval is not obtained in November, runway is expected through 2024.

Ashleigh Palmer said the FDA interaction has been constructive and that the proposed label and post-marketing terms were broadly in line with prior public guidance, while emphasizing that final approval is still uncertain. He framed teplizumab as potentially the first disease-modifying therapy for at-risk Stage 2 T1D and said the company is moving ahead on both regulatory and commercial preparation. He also highlighted ongoing pipeline progress in PROTECT, PREVAIL II, ordesekimab, and PRV-101, signaling a broader autoimmune strategy beyond teplizumab.

Thierry Chauche focused on the quarter’s financial profile and liquidity. He cited a $28.6 million net loss, $16.3 million of R&D, $13.5 million of G&A, and $0.8 million of collaboration revenue, and noted the company’s cash-based operating expenses came in at $26.4 million, slightly below guidance, due to cautious spending. He detailed liquidity of $186.5 million at quarter-end, plus a $20 million Sanofi payment received in October, a potential $35 million equity purchase from Sanofi if teplizumab is approved, and a possible $40 million Hercules draw, while reiterating runway through 2023 if approved and through 2024 if not.

Analysts focused on pricing, post-marketing requirements, CMC/manufacturing, payer access, launch metrics, Europe, and the Sanofi right of first negotiation. Management said final pricing will not be set until the label is final, but payer feedback has been consistent that teplizumab should be coverable with a streamlined prior authorization approach. On post-marketing commitments, management said they expect a pediatric safety study, PK/PD study in patients under 8, and a long-term safety registry, while also clarifying that Sanofi can extend its right of first negotiation into the period when PROTECT data are expected.